Chlamydia Infection Diagnostics and Therapeutics Market Overview
Chlamydia is a sexually transmitted disease. The symptoms do not show early on. It is usually prevailing in the areas with poor sanitation. It is the most common STD worldwide. Number of victims has been increasing over the last decade.
Increasing number of cases of these diseases, better reporting in emerging economies, augmenting screening coverage, improved funding for the better R&D in this area, growing awareness regarding STDs in the developing countries along with increased healthcare expenditures, these are the factors driving the growth of this market. Also accessibility and availability of hyper sensitive diagnostic tests are also boosting the growth of this market. Additionally, improved insurance coverage in the emerging economies augurs well for this market. However, the stigma associated with this sexually transmitted diseases is the primary restraint of market growth.
Chlamydia Infection Diagnostics and Therapeutics Market Forecast Report (2018-2023)
The Global Chlamydia Infection Diagnostics and Therapeutics market size was around USD 2.25 billion in 2018. It is expected to grow at the CAGR of 6% to reach USD 3.01 billion by 2023.
Browse Report Brief and TOC @ https://www.marketdataforecast.com/market-reports/chlamydia-infection-diagnostics-and-therapeutics-market-5132/
Chlamydia Infection Diagnostics and Therapeutics Market Segmentation
Chlamydia Infection Diagnostics and Therapeutics Market is broadly segmented by product type and end user into diagnostics and therapeutics segments. Classification in the diagnostics by product type entails Nucleic Acid Amplification Tests (NAATs), Direct Fluorescent Tests, and PCR. NAAT accounted for the largest market share in 2016 and this is predicted to grow robustly in the forecast period. It is closely tailed by the DFT in terms of CAGR. This is because NAATs are more sensitive and diagnose better. Classification in diagnostics by end user entails Hospitals, Specialty Clinics, and Diagnostic Centres. Classification in the therapeutics by product type entails Macrolides, Quinolones, Sulphonamides, Tetracycline, and Aminopenicillins. Macrolides is expected to undergo the high growth in the forecast period. It also captures the largest market share and it is expected to stay at the top in the forecast period.
Classification by geography is done into North America, Latin America, Europe, Asia Pacific, Middle East and Africa. North America is the largest regional market while Asia Pacific is expected to be the fastest growing market worldwide.
- Key players in the market include
- Bio Rad laboratories
- Novartis AG
- F Hoffmann-La Roche
- Abbott Laboratories
- DiaSorin SpA
- Siemens AG
- Thermo Fisher Scientific
- Becton Dickinson and Company
In order to be a part of competition, these companies are highly focusing on the new product launch, expansion of business across regions, and improving product portfolio. For this, they are adopting strategies such as acquisitions, mergers, and collaborations.
Market Data Forecast is the firm working in the areas of market research, business intelligence and consulting. We have a great experience in research and consulting for various business domains to cater the needs of both individual and corporate clients.